99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
99.5% of patients were already receiving the max tolerated dose of a RASi at baseline, & just over half (53.2%) were #flozinated
About 60% had 1+ or more hematuria, with proteinuria 2 g/day & preserved GFR (60 ml/min).
Are these the patients you most often encounter with IgAN?
Strengths
Patients were already receiving standard of care treatment: nearly all were on maximal RAS blockade & more than 1/2 were on an SGLT2i.
This is in contrast to NEFIGARD where almost no one was #flozinated - likely reflecting the evolution of evidence & growing access.
Strengths
Patients were already receiving standard of care treatment: nearly all were on maximal RAS blockade & more than 1/2 were on an SGLT2i.
This is in contrast to NEFIGARD where almost no one was #flozinated - likely reflecting the evolution of evidence & growing access.
Only 0.4% were flozinated & only 4% were glipinated, #nephjc🤓😀
Only 0.4% were flozinated & only 4% were glipinated, #nephjc🤓😀